OVARIAN MUCINOUS CYSTADENOCARCINOMA
Clinical trials for OVARIAN MUCINOUS CYSTADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN MUCINOUS CYSTADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN MUCINOUS CYSTADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Ovarian cancer showdown: which chemo combo works best?
Disease control OngoingThis study tests two different chemotherapy combinations (carboplatin+paclitaxel vs oxaliplatin+capecitabine), with or without the targeted drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 patients with newly diagnosed or recurrent dise…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: OVARIAN MUCINOUS CYSTADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC